Evidence map›Paper›PMID 19400893›Full record

Trial reportClinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology2009

Safety of hookworm infection in individuals with measurable airway responsiveness: a randomized placebo-controlled feasibility study.

J Feary, A Venn, A Brown, D Hooi, F H Falcone, K Mortimer, D I Pritchard, J Britton

Open access · bronzeAbstract readRandomized Controlled Trial
In one paragraph

Trial report in Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 2 pooled it
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 2 syntheses or guidelines pooled it, 98 citations in OpenAlex.

  1. Pooled it
  2. Helminth therapy (worms) for allergic rhinitis.The Cochrane database of systematic reviews · 2012
    Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Trial
  7. Experimental hookworm infection: a randomized placebo-controlled trial in asthma.Clinical and experimental allergy : journal of the British Society for Allergy and Clinical Immunology · 2010
    Trial
  8. Isolation ofF1000Research · 2026
    Article
  9. Review
  10. Review
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
  17. Review
  18. The yin and yang of human soil-transmitted helminth infections.International journal for parasitology · 2021
    Review
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 1 institution in 1 country.

J FearyDivision of Epidemiology and Public Health, University of Nottingham, UK. johanna.feary@nottingham.ac.uk
A Venn
A Brown
D Hooi
F H Falcone
K Mortimer
D I Pritchard
J Britton
University of Nottingham · GB

Funding

Wellcome Trust GR065978MAWellcome Trust GR076306/2/04/2
6 · The paper itself

Abstract

backgroundEpidemiological evidence suggests that hookworm infection protects against asthma. However, for ethical and safety reasons, before testing this hypothesis in a clinical trial in asthma it is necessary to establish whether experimental hookworm infection might exacerbate airway responsiveness during larval lung migration.

objectiveTo determine whether hookworm larval migration through the lungs increases airway responsiveness in allergic individuals with measurable airway responsiveness but not clinical asthma, and investigate the general tolerability of infection and effect on allergic symptoms.

methodsThirty individuals with allergic rhinoconjunctivitis and measurable airway responsiveness to adenosine monophosphate (AMP) but not clinically diagnosed asthma were randomized, double-blind to cutaneous administration of either 10 hookworm larvae or histamine placebo, and followed for 12 weeks. The primary outcome was the maximum fall from baseline in provocative dose of inhaled AMP required to reduce 1-s forced expiratory volume by 10% (PD(10)AMP) measured at any time over the 4 weeks after active or placebo infection. Secondary outcomes included peak flow variability in the 4 weeks after infection, rhinoconjunctivitis symptom severity and adverse effect diary scores over the 12-week study period, and change in allergen skin test responses between baseline and 12 weeks.

resultsMean maximum change in PD(10)AMP from baseline was slightly but not significantly greater in the hookworm than the placebo group (-1.67 and -1.16 doubling doses; mean difference -0.51, 95% confidence interval -1.80 to 0.78, P=0.42). Symptom scores of potential adverse effects were more commonly reported in the hookworm group, but infection was generally well tolerated. There were no significant differences in peak-flow variability, rhinoconjunctivitis symptoms or skin test responses between groups.

conclusionHookworm infection did not cause clinically significant exacerbation of airway responsiveness and was well tolerated. Suitably powered trials are now indicated to determine the clinical effectiveness of hookworm infection in allergic rhinoconjunctivitis and asthma.

Indexed as

Adenosine MonophosphateAdolescentAdultAsthmaBronchial HyperreactivityBronchial Provocation TestsConjunctivitis, AllergicDouble-Blind MethodFeasibility StudiesFemaleFollow-Up StudiesForced Expiratory VolumeHookworm InfectionsHumansMalePlacebosAdenosine MonophosphatePlacebos

Identifiers

PMID19400893
PMCPMC2728895
OpenAlexW2168752274

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.